Tier 2 — strong

Long-term treatment with calcium-alpha-ketoglutarate corrects secondary hyperparathyroidism

Zimmermann E, Wassmer S, Steudle V
Mineral and Electrolyte Metabolism 1996 22(1-3):196-199

Bibliography

PubMed
PMID 8676818
Funding
Funding information is not available in the PubMed record reviewed for this entry.
Competing interests
Competing-interest information is not reported in the PubMed record reviewed for this entry.

Study snapshot

DesignLong-term clinical intervention in hemodialysis patients with secondary hyperparathyroidism.
ModelMaintenance hemodialysis patients.
Sample14 patients.
InterventionMean 4.5 g/day calcium alpha-ketoglutarate, supplying about 0.975 g elemental calcium.
Duration36 months.
EndpointsSerum phosphate; Serum calcium; Calcium/phosphate ratio; Intact parathyroid hormone

What the study showed, in plain terms

This is one of the longest human Ca-AKG exposure studies located in the literature.

Fourteen hemodialysis patients received a mean of 4.5 g/day for three years. Phosphate fell, calcium rose and intact parathyroid hormone normalized during treatment.

It is valuable for long-duration exposure and mineral-metabolism context, but it is a renal-disease study and does not establish long-term safety or efficacy in healthy adults.

Key findings

  • Mean exposure was 4.5 g/day for 36 months.
  • Serum phosphate decreased and serum calcium increased.
  • Intact parathyroid hormone fell markedly during treatment.

What this study can and cannot tell us

  • Small uncontrolled clinical cohort.
  • Participants had advanced kidney disease and abnormal mineral metabolism.
  • The dose and clinical indication are very different from modern longevity supplementation.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology